Beerse, Belgium – Janssen Pharmaceutica N.V., (Janssen) today announced a research agreement to collaborate with GE Healthcare to develop non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimer’s disease prior to the onset of clinical symptoms. Pre-symptomatic biosignatures will allow earlier diagnosis of the disease and may enable significantly earlier intervention in Alzheimer’s disease. This […]

Sale Completes Strategic Transition to a Pharmaceutical Company with a PDUFA date for vilazodone in January 2011 NEWTON, Mass. – Clinical Data, Inc. (NASDAQ: CLDA) today announced that it has signed a definitive asset purchase agreement with Transgenomic, Inc. (OTCBB: TBIO) to sell its genetic and pharmacogenomic testing and biomarker development business for approximately $15.4 […]

Development and Supply of a Dedicated Diagnostics Iinstrument – Agreement building upon established OEM partnership between both companies – Concept development and feasibility testing already successfully completed – Tecan signed a ten-year supply agreement with a purchase commitment by the diagnostic company – Upon successful completion of development, based on Tecan’s expectations sales potential is […]

QIAGEN selected by UN Food and Agriculture Organization and International Atomic Energy Agency to initially supply up to 50 molecular testing devices for use in 35 emerging countries Lightweight portable devices will enable ultra-fast testing of DNA and RNA to pinpoint livestock infections at source Pilot project targets three common diseases that disrupt food supplies, […]